Your browser doesn't support javascript.
loading
The Effects of L-Carnitine Supplementation on Weight Loss, Glycemic Control, and Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Systematic Review and Dose-response Meta-Analysis of Randomized Controlled Trials.
Mirrafiei, Amin; Jayedi, Ahmad; Shab-Bidar, Sakineh.
Affiliation
  • Mirrafiei A; Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
  • Jayedi A; Social Determinant of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran.
  • Shab-Bidar S; Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Iran; Sports Medicine Research Center, Neuroscience Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran. Electronic address: s_shabbidar@tums.ac.ir.
Clin Ther ; 46(5): 404-410, 2024 May.
Article in En | MEDLINE | ID: mdl-38594107
ABSTRACT

PURPOSE:

L-carnitine supplementation has been recommended to improve cardiometabolic health markers in diabetic patients. Our purpose was to assess the dose-dependent effects of l-carnitine supplementation on cardiometabolic risk factors in patients with type 2 diabetes.

METHODS:

PubMed/Medline, Scopus, and Web of Science were searched until May 2022 for randomized controlled trials that examined the impact of l-carnitine supplementation on cardiometabolic risk factors in adults with type 2 diabetes. The mean difference (MD) and its 95% confidence interval (CI) were estimated utilizing a random-effects model. Nonlinear dose-response associations were modeled with restricted cubic splines. The certainty of evidence was rated using the GRADE approach.

FINDINGS:

Twenty-one randomized trials with 2041 patients with type 2 diabetes were included. We found that every 1 g/d supplementation with l-carnitine significantly reduced body mass index (MD -0.37 kg/m2, 95% CI -0.59, -0.15; I2 =93%, n=13, GRADE=low), HbA1c (MD -0.16%, 95% CI -0.32, -0.01; I2 = 94%, n = 18, GRADE = moderate), and low-density lipoprotein cholesterol (MD -0.11 mmol/L, 95% CI -0.16, -0.05; I2 = 91%, n = 11, GRADE = high). There were also reductions in serum triglycerides (MD 0.07 mmol/L), total cholesterol (MD -0.13 mmol/L), and fasting plasma glucose (MD -0.17 mmol/L). A U-shaped effect was demonstrated for body mass index, with the largest reduction at 2 g/d. A linear reduction was seen for serum triglycerides, total cholesterol, and fasting plasma glucose up to l-carnitine supplementation of 4 g/d. IMPLICATIONS L-carnitine supplementation resulted in a small reduction in serum lipids and plasma glucose in patients with type 2 diabetes. However, due to high statistical heterogeneity, the results should be interpreted very cautiously.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Blood Glucose / Carnitine / Weight Loss / Dietary Supplements / Diabetes Mellitus, Type 2 / Glycemic Control Language: En Journal: Clin Ther Year: 2024 Type: Article Affiliation country: Iran

Full text: 1 Database: MEDLINE Main subject: Blood Glucose / Carnitine / Weight Loss / Dietary Supplements / Diabetes Mellitus, Type 2 / Glycemic Control Language: En Journal: Clin Ther Year: 2024 Type: Article Affiliation country: Iran